MedTech improvements align a 150-year-old researched clinical treatment to 2019 commissioning guidelines
In 2018/19 the NHS consultation ‘Evidence Based Interventions’ (https://www.england.nhs.uk/wp-content/uploads/2018/06/04-b-pb-04-07-2018-ebi-consultation-document.pdf) concluded that 17 specified treatments do not add value on a health population economic scale in their current format.
For many patients, such as the reported 8 million haemorrhoid suffers in the UK, this left little help or direction as to where they could be sign-posted for effective care and support. Thankfully many CCGs have gone beyond the superficial and elementary scope reduction and cost cutting opportunity and are genuinely looking at the opportunity to improve care, patient access and benefit, reduce service risk as well as increase the value of spending by improved outcomes, increased numbers or budget savings.
In the case of haemorrhoid surgery, the guidance refers to more effective comparative treatment being better carried out in a clinic rather than theatre setting.
In parallel, a small and rapidly developing company in Sandwich, England, has taken a US progressive technology and brought its manufacturing to the UK to enable a new, low risk, fully ambulatory treatment which embodies the spirit and requirement of the commissioning guidance.
Little known in the UK to many practitioners, electrotherapy for the treatment of Haemorrhoids is a method with over a 150 years of clinic research behind it. With over 155,000 treatments in the US and now 3,000 in the UK (privately). The procedure has demonstrated a high degree of patient benefit and an exceptionally low level of complication rates. This has convinced a number of sceptical Surgical Consultants, who given the results they have achieved and the feedback from their patients, have adopted the treatment. NICE have also awarded the treatment MIB recommendation status and there is an increasing level of backing to pilot, prove and adopt the service on a much wider scale across the NHS.
Given 1 in 4 people will suffer at some point from haemorrhoids, the team behind eXroid are keen to raise awareness and promote the significant benefits that this treatment has delivered.
They also want to directly support NHS staff directly by subsidising treatments by 10%, appreciating that this can be a debilitating and demoralising condition.
For more information please see exroid.com or call 0800 999 3777 and Quote NHS along with your NHS email address